The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Morphologic and genomic characterization of circulating tumor cells in patients with metastatic colorectal cancer treated with combinational treatment of andecaliximab, bevacizumab and chemotherapy.
 
Stephanie Shishido
No Relationships to Disclose
 
Peter Kuhn
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Epic Sciences; Fluidigm; Novartis
Research Funding - Abbvie; Amgen; Daiichi Sankyo; Fluidigm; Gilead Sciences; Kite, a Gilead company; Lilly; Novartis
Patents, Royalties, Other Intellectual Property - HD-SCA technology was developed by myself and members of my team while at The Scripps Research Institute, which has subsequently licensed the technology to Epic Sciences for exclusive commercial development.
Expert Testimony - BDMK Law